Abstract
Mitoxantrone has been associated with the severe adverse effects of cardiotoxicity and myelocytic leukemia. Therefore, in considering mitoxantrone as a treatment option for people with multiple sclerosis (MS), it is important to determine whether the possible benefits outweigh the considerable risks. In a retrospective evaluation of patients who had received mitoxantrone in our MS center, we noted unexpectedly better outcomes in six African Americans with secondary progressive multiple sclerosis (SPMS) compared with six white patients with similar characteristics. Although this sample is small, if it is typical, the findings may provide support for the use of mitoxantrone in African American people with MS and indicate a need to evaluate MS patients' responses to treatment by ethnicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
